If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
== Causes == The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors. While some of these factors are under personal control, such as diet and obesity, other factors are not, such as increasing age, female sex, and genetics. Generous consumption of alcohol is also a risk factor. Obesity is more common in women than men in many parts of Africa. The nutritional status of a mother during fetal development may also play a role.
Throughout the 2012/13 offseason, the league investigated the Melbourne Football Club over allegations that it had tanked during the latter part of the 2009 season – that is, that it had intentionally lost matches near the end of the season so that it would finish with no more than four wins, and therefore receive a priority draft pick. The league released its findings in February 2013, and found the club not guilty of tanking. However, it did find two of Melbourne's then-senior staff members – senior coach Dean Bailey and general manager of football operations Chris Connolly – guilty of "acting in a manner prejudicial to the interests of the competition". This related most specifically to a meeting in July 2009, which became known colloquially as "the vault", in which Connolly allegedly openly discussed the potential benefits to the club of tanking. The guilty parties received the following penalties:
==== Phosphodiesterase PDE5 inhibitors ==== Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [114] Lodenafil (CRIS-031; Helleva) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [115] Mirodenafil (Aibishi; Bravonto; Mvix; SK-3530) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [116] Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [117] Sildenafil chewable tablets (Nurigra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [118] Sildenafil orally soluble film (sildenafil ODF; SPO-1101; Vultis) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [119] Sildenafil orally soluble film (orodispersible sildenafil; Please; sildenafil oral dissolving film; sildenafil orally-disintegrating film; sildenafil OSF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [120] Sildenafil oral spray (ASP-001; ASP-002; Bandol; Hezkue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [121] Sildenafil oro-dispersible tablets (Erecta; FACSID-50) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [122] Simmerafil (Onvita; Onweida; semenafil; TPN-171; TPN-171-H) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [123] Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [124] Tadalafil oral disintegrating film (SPO-1102; Vulteum; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [125] Tadalafil oral film (OGOOD) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [126] Udenafil (DA-8159; Jurvigo; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [127] Vardenafil (BAY-389456; Levitra; Nuviva; Staxyn; vardenafil ODT; vardenafil orodispersible tablet; Vivanza) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [128]
Turner also told Newshub programme The Project, that doing a "one-off emergency screening to get blood from someone who is unvaccinated" might create the impression that there is a potential problem, and urged people to "sit down and work through where their fears and anxieties", concluding that the New Zealand health services were offering the best quality service to the baby.
The menu is created by Bosi. He has been described as an innovator and his work has been compared to that of Heston Blumenthal at The Fat Duck. One of the new dishes Bosi introduced following his move to London was a two-part pork dish. The first part was roasted suckling pig served with sea urchin, kohlrabi and a fondant of sweet potato. The second, inspired by his daughter, featured a sausage roll with a salad and a truffle dressing. Other dishes have included roast chicken with an onion fondue and licorice, and desserts include a chocolate tart served with basil ice cream. Bosi uses molecular gastronomy techniques, such as in the process for making a Savoy cabbage purée, in which the cabbage is freeze dried into a powder and then reconstituted, but he prefers only to enhance the flavours of individual ingredients rather than changing those flavours by using unusual techniques.
Sources: en.wikipedia.org
=== Basal rate determination === Basal insulin requirements will vary between individuals and periods of the day. The basal rate for a particular time period is determined by fasting while periodically evaluating the blood sugar level. Neither food nor bolus insulin must be taken for 4 hours before or during the evaluation period. If the blood sugar level changes dramatically during evaluation, then the basal rate can be adjusted to increase or decrease insulin delivery to keep the blood sugar level approximately steady. For instance, to determine an individual's morning basal requirement, they must skip breakfast. On waking, they would test their blood glucose level periodically until lunch. Changes in blood glucose level are compensated with adjustments in the morning basal rate. The process is repeated over several days, varying the fasting period, until a 24-hour basal profile has been built up which keeps fasting blood sugar levels relatively steady. Once the basal rate is matched to the fasting basal insulin need, the pump user will then gain the flexibility to skip or postpone meals such as sleeping late on the weekends or working overtime on a weekday. Many factors can change insulin requirements and require an adjustment to the basal rate:
By doing so, individuals with masculinized brains are better able to survive and copulate with as many mates as possible. The masculinization of the brain is mediated both by testosterone levels at the adult stage and by testosterone exposure in the womb. Higher pre-natal testosterone indicated by a low digit ratio as well as adult testosterone levels increased risk of fouls or aggression among male players in a soccer game. Studies have found higher pre-natal testosterone or lower digit ratio to be correlated with higher aggression. The rise in testosterone during competition predicted aggression in males, but not in females. In one experiment, subjects who interacted with handguns showed higher testosterone levels and aggression than those who interacted with toys. One study proposed that natural selection may have caused men to be more sensitive to situations in which their status is challenged, and that testosterone is the key factor that causes these situations to spark into aggression. Structural brain characteristics associated with testosterone levels have also been found to predict individuals' levels of aggression. The Annals of the New York Academy of Sciences has found that the use of anabolic steroids (which increases testosterone) among teenagers is correlated with increased likelihood of using violence. One study found that administering testosterone increased verbal aggression in some participants. A few studies indicate that the testosterone derivative estradiol might play an important role in male aggression.
Three vessels traveling in a convoy were struck on 30 December, killing three people. After the first vessel was hit, an unknown number of survivors jumped overboard from the other two vessels before they were sunk. Unnamed sources reported at least six, and possibly eight survivors. On 2 January 2026, US Coast Guard suspended a search for survivors southwest of the Mexican–Guatemalan border, in the fourth strike where crew members survived the initial strike. A 23 January strike killed two people and left one survivor, for whom the US Coast Guard activated a search-and-rescue mission. A 5 February strike on an alleged Designated Terrorist Organization killed two people. A US military strike on 9 February killed two people and left one survivor for whom the Maritime Rescue Coordination Center Ecuador launched a search-and-rescue mission with technical assistance from the US Coast Guard. On 16 February, the US struck two boats in the Pacific, killing four people per boat. A 20 February strike killed three people. An 8 March strike killed six. A 19 March strike killed two and left one survivor who was captured. A 18 June strike killed three.
One potential scenario that has been envisioned is out-of-control self-replicating molecular assemblers in the form of gray goo which consumes carbon to continue its replication. If unchecked, such mechanical replication could potentially consume whole ecoregions or the whole Earth (ecophagy), or it could simply outcompete natural lifeforms for necessary resources such as carbon, ATP, or UV light (which some nanomotor examples run on). However, the ecophagy and 'grey goo' scenarios, like synthetic molecular assemblers, are based upon still-hypothetical technologies that have not yet been demonstrated experimentally.
=== Anxiety disorders === Paroxetine was the first antidepressant approved in the United States for the treatment of panic disorder. Several studies have concluded that paroxetine is superior to placebo in the treatment of panic disorder. Paroxetine has demonstrated efficacy for the treatment of social anxiety disorder in adults and children. It is also beneficial for people with co-occurring social anxiety disorder and alcohol use disorder. It appears to be similar to a number of other SSRIs. Paroxetine is used in the treatment of obsessive-compulsive disorder. Comparative efficacy of paroxetine is equivalent to that of clomipramine and venlafaxine. Paroxetine is also effective for children with obsessive-compulsive disorder. Paroxetine is approved for the treatment of PTSD in the United States, Japan, and Europe. In the United States, it is approved for short-term use. Paroxetine is also FDA-approved for generalized anxiety disorder.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.